Surgical robots as a set of a number of modern high-tech means in one of the complex, applied to part of the clinical operation of the medical equipment, by the surgeon using the main console through remote control and manipulation of the end equipment connected to the robotic arm to complete the operation. Compared with traditional surgery, surgical robots can provide doctors with a high-definition three-dimensional surgical field of vision; operation can be realized beyond the manual degree of flexibility and precision; the patient’s wound trauma surface is smaller, can reduce the wound exposure and the risk of infection and so on.
In the field of surgical robots, the U.S. robot-assisted minimally invasive surgery technology company Intuitive Surgical is the undisputed king. Founded in 1995, Intuitive Surgical only focuses on the research of robotic surgical systems, won the favor of many capital, since 2000 listed on NASDAQ, with its da Vinci surgical robots, monopolizing the global market of laparoscopic surgical robots for nearly 20 years.
However, in the case of the da Vinci laparoscopic surgical robot, for example, a machine is priced at about 20 million yuan, and, each unit has been used only 730 times cumulatively. This means a start-up cost of 30,000 RMB for each surgery, as well as annual consumables and maintenance costs of up to a million dollars. These high costs are ultimately borne by the consumer, which is undoubtedly a significant expense for the patient. If the domestic surgical robot can be close to the quality of the da Vinci robot under the premise of providing a more competitive price, or can effectively enter a wide range of domestic untapped gap in the market.
With the introduction of a series of favorable government policies on surgical robots, China’s surgical robot industry is expected to flourish. 2012, the State Council issued the “bio-industry development plan” has been mentioned in the development of a new generation of minimally invasive, non-invasive and general medical diagnostic and treatment equipment and testing equipment, surgical instruments and robots. 2015, in the “made in china 2025” re-emphasized the development of medical robots and other high-performance diagnostic and treatment equipment as the focus. In 2015, the “Made in China 2025” re-emphasized the development of medical robots and other high-performance diagnostic and therapeutic equipment as a key focus. 2022 issued the “14th Five-Year Plan for the Development of the Pharmaceutical Industry” to promote the application of information technology, such as artificial intelligence in the field of medical devices.
In the first half of 2022, a total of nine surgical robots were approved by the NMPA, which is a big increase compared with the number of six robots in the whole year of 2021. Among them, three models of knee replacement surgical robots, two each of laparoscopic surgical robots and spinal surgical robots, and one each of hip replacement surgical robots and neurosurgical surgical robots.
And on June 14, 2022,Perlove Medical’s self-developed orthopedic surgical robot received marketing approval from the National Drug Administration (NMPA). The approval of Perlove Medical’s listing will further break the monopoly of imported products on the domestic orthopedic joint robot market, promote the rapid development of China’s smart orthopedic surgical robots, further realize accurate medical treatment, and create conditions for the surgical robotics technology to sink into the grass-roots hospitals and benefit more patients.
At present, the domestic substitution of surgical robots will be a more feasible direction, the domestic research and development of surgical robots in various disciplines into the state of blossoming, the industry is becoming more and more prosperous, surgical robots are more towards the trend of specialization. Domestic luminal and orthopedic surgical robots approved for listing the number of surgical robots is increasing rapidly, the surgical robot market has great potential.